Skip to Main Content

Paper Details

Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with <i>BRAF</i> p.T599dup mutation.
Cold Spring Harb Mol Case Stud
7
2021
BRAF, BRAF p, BRAF p.T599dup, BRAF p.T599dup mutation, BRAF p.V600E/K mutation, BRAF-mutated tumor, MEK, T599dup, T599dup mutation, V600E, World, central nervous system, dabrafenib, ganglioglioma, headaches, non-V600E BRAF-mutated tumor, p.V600E, patient, patients, pediatric, peripheral neuropathy, primary brain tumors, trametinib, tumor, tumors, vinblastine
Author NameAffiliation
Katherine E MillerThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital
Kathleen M SchiefferThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital
Catherine E CottrellThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital
Catherine E CottrellThe Ohio State University College of Medicine
Catherine E CottrellThe Ohio State University College of Medicine
Jonathan L FinlayThe Ohio State University College of Medicine
Jonathan L FinlayNationwide Children's Hospital
Elaine R MardisThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital
Elaine R MardisThe Ohio State University College of Medicine
Elaine R MardisThe Ohio State University College of Medicine
Elaine R MardisThe Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital
Elaine R MardisThe Ohio State University College of Medicine
Elaine R MardisThe Ohio State University College of Medicine
  • 1 - 13

Datasets

Release 1.2